Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

16 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

Corticosteroid Medication Week 38 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 38

- 14-07-17 - 1 Formulier, 1 Itemgroep, 1 Data-element, 1 Taal
Itemgroep: Corticosteroid Medication
Study part: Corticosteroid Medication Week 38/ Early Withdrawal visit. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 32 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 32

- 12-07-17 - 1 Formulier, 1 Itemgroep, 1 Data-element, 1 Taal
Itemgroep: Corticosteroid Medication
Study part: Corticosteroid Medication Week 32. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 28 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 28

- 12-07-17 - 1 Formulier, 1 Itemgroep, 1 Data-element, 1 Taal
Itemgroep: Corticosteroid Medication
Study part: Corticosteroid Medication Week 28. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 24 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 24

- 12-07-17 - 1 Formulier, 1 Itemgroep, 1 Data-element, 1 Taal
Itemgroep: Corticosteroid Medication
Study part: Corticosteroid Medication Week 24. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 20 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 20

- 12-07-17 - 1 Formulier, 1 Itemgroep, 1 Data-element, 1 Taal
Itemgroep: Corticosteroid Medication
Study part: Corticosteroid Medication Week 20. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 16 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 16

- 12-07-17 - 1 Formulier, 1 Itemgroep, 1 Data-element, 1 Taal
Itemgroep: Corticosteroid Medication
Study part: Corticosteroid Medication Week 16. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Weeks 9- 11 Mepolizumab HES NCT00086658 - Corticosteroid Medication Weeks 9- 11

- 10-07-17 - 1 Formulier, 1 Itemgroep, 1 Data-element, 1 Taal
Itemgroep: Corticosteroid Medication
Study part: Corticosteroid Medication Weeks 9- 11. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 12 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 12

- 10-07-17 - 1 Formulier, 1 Itemgroep, 1 Data-element, 1 Taal
Itemgroep: Corticosteroid Medication
Study part: Corticosteroid Medication Week 12. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 8 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 8

- 09-07-17 - 1 Formulier, 1 Itemgroep, 1 Data-element, 1 Taal
Itemgroep: Corticosteroid Medication
Study part: Corticosteroid Medication Week 8. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Weeks 5 - 7 Mepolizumab HES NCT00086658 - Corticosteroid Medication Weeks 5 - 7

- 09-07-17 - 1 Formulier, 1 Itemgroep, 1 Data-element, 1 Taal
Itemgroep: Corticosteroid Medication
Study part: Corticosteroid Medication Weeks 5 - 7. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 4 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 4

- 11-06-17 - 1 Formulier, 1 Itemgroep, 1 Data-element, 1 Taal
Itemgroep: Corticosteroid Medication
Study part: Corticosteroid Medication Week 4. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 1-3 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 1-3

- 11-06-17 - 1 Formulier, 1 Itemgroep, 1 Data-element, 1 Taal
Itemgroep: Corticosteroid Medication
Study part: Corticosteroid Medication Week 1-3. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial